370 related articles for article (PubMed ID: 28150186)
21. Serelaxin a novel treatment for acute heart failure.
Castrini AI; Carubelli V; Lazzarini V; Bonadei I; Lombardi C; Metra M
Expert Rev Clin Pharmacol; 2015; 8(5):549-57. PubMed ID: 26294074
[TBL] [Abstract][Full Text] [Related]
22. Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study.
Meyer S; Teerlink JR; Metra M; Ponikowski P; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Hua TA; Severin T; Qian M; Voors AA
Clin Res Cardiol; 2017 Apr; 106(4):280-292. PubMed ID: 27838739
[TBL] [Abstract][Full Text] [Related]
23. Representativeness of RELAX-AHF clinical trial population in acute heart failure.
Wang TS; Hellkamp AS; Patel CB; Ezekowitz JA; Fonarow GC; Hernandez AF
Circ Cardiovasc Qual Outcomes; 2014 Mar; 7(2):259-68. PubMed ID: 24594552
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic effects of serelaxin in acute heart failure.
Du XJ; Hewitson TD; Nguyen MN; Samuel CS
Circ J; 2014; 78(3):542-52. PubMed ID: 24451687
[TBL] [Abstract][Full Text] [Related]
25. Targeted biological therapies reach the heart: the case of serelaxin for heart failure.
Kumar VA; Wilson SS; Ayaz SI; Levy PD
Drugs Today (Barc); 2015 Oct; 51(10):591-7. PubMed ID: 26583301
[TBL] [Abstract][Full Text] [Related]
26. Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study.
Cotter G; Voors AA; Prescott MF; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Milo O; Hua TA; Qian M; Severin TM; Teerlink JR; Metra M; Davison BA
Eur J Heart Fail; 2015 Nov; 17(11):1133-43. PubMed ID: 26333529
[TBL] [Abstract][Full Text] [Related]
27. Design of the RELAXin in acute heart failure study.
Ponikowski P; Metra M; Teerlink JR; Unemori E; Felker GM; Voors AA; Filippatos G; Greenberg B; Teichman SL; Severin T; Mueller-Velten G; Cotter G; Davison BA
Am Heart J; 2012 Feb; 163(2):149-55.e1. PubMed ID: 22305830
[TBL] [Abstract][Full Text] [Related]
28. Serelaxin: a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actions.
Díez J
Am J Cardiovasc Drugs; 2014 Aug; 14(4):275-85. PubMed ID: 24590581
[TBL] [Abstract][Full Text] [Related]
29. Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF.
Metra M; Davison BA; Gimpelewicz C; Carubelli V; Felker GM; Filippatos G; Greenberg BH; Hua TA; Liu Z; Pang PS; Ponikowski P; Severin TM; Voors AA; Wang Y; Cotter G; Teerlink JR
Int J Cardiol; 2018 Feb; 253():91-96. PubMed ID: 29306479
[TBL] [Abstract][Full Text] [Related]
30. Right ventricular dysfunction is a strong predictor of developing atrial fibrillation in acutely decompensated heart failure patients, ACAP-HF data analysis.
Aziz EF; Kukin M; Javed F; Musat D; Nader A; Pratap B; Shah A; Enciso JS; Chaudhry FA; Herzog E
J Card Fail; 2010 Oct; 16(10):827-34. PubMed ID: 20932465
[TBL] [Abstract][Full Text] [Related]
31. Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Trial.
Abualnaja S; Podder M; Hernandez AF; McMurray JJ; Starling RC; O'Connor CM; Califf RM; Armstrong PW; Ezekowitz JA
J Am Heart Assoc; 2015 Aug; 4(8):e002092. PubMed ID: 26304935
[TBL] [Abstract][Full Text] [Related]
32. Neutrophil-to-Lymphocyte Ratio and Outcomes in Patients Admitted for Acute Heart Failure (As Seen in the BLAST-AHF, Pre-RELAX-AHF, and RELAX-AHF Studies).
Davison BA; Takagi K; Edwards C; Adams KF; Butler J; Collins SP; Dorobantu MI; Ezekowitz JA; Filippatos G; Greenberg BH; Levy PD; Masip J; Metra M; Pang PS; Ponikowski P; Severin TM; Teerlink JR; Teichman SL; Voors AA; Werdan K; Cotter G
Am J Cardiol; 2022 Oct; 180():72-80. PubMed ID: 35933224
[TBL] [Abstract][Full Text] [Related]
33. Relaxin for the Treatment of Acute Decompensated Heart Failure: Pharmacology, Mechanisms of Action, and Clinical Evidence.
Ng TM; Goland S; Elkayam U
Cardiol Rev; 2016; 24(4):194-204. PubMed ID: 26331289
[TBL] [Abstract][Full Text] [Related]
34. Intravenous metoprolol versus diltiazem for atrial fibrillation with concomitant heart failure.
Compagner CT; Wysocki CR; Reich EK; Zimmerman LH; Holzhausen JM
Am J Emerg Med; 2022 Dec; 62():49-54. PubMed ID: 36252310
[TBL] [Abstract][Full Text] [Related]
35. Recent developments in the treatment of heart failure: highlights from the American Heart Association's Scientific Sessions, Los Angeles, California, 3 - 7 December 2012.
von Haehling S
Expert Opin Investig Drugs; 2013 Jul; 22(7):933-7. PubMed ID: 23656525
[TBL] [Abstract][Full Text] [Related]
36. Disconnect between the effects of serelaxin on renal function and outcome in acute heart failure.
Beldhuis IE; Ter Maaten JM; Figarska SM; Damman K; Pang PS; Greenberg B; Davison BA; Cotter G; Severin T; Gimpelewicz C; Felker GM; Filippatos G; Teerlink JR; Metra M; Voors AA
Clin Res Cardiol; 2023 Jul; 112(7):901-910. PubMed ID: 36656377
[TBL] [Abstract][Full Text] [Related]
37. Recombinant human H2 relaxin (serelaxin) as a cardiovascular drug: aiming at the right target.
Bani D
Drug Discov Today; 2020 Jul; 25(7):1239-1244. PubMed ID: 32360533
[TBL] [Abstract][Full Text] [Related]
38. Serelaxin for the treatment of heart failure.
Moin DS; Bloom MW; Papadimitriou L; Butler J
Expert Rev Cardiovasc Ther; 2016 Jun; 14(6):667-75. PubMed ID: 27045761
[TBL] [Abstract][Full Text] [Related]
39. Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial.
Corcoran D; Radjenovic A; Mordi IR; Nazir SA; Wilson SJ; Hinder M; Yates DP; Machineni S; Alcantara J; Prescott MF; Gugliotta B; Pang Y; Tzemos N; Semple SI; Newby DE; McCann GP; Squire I; Berry C
Cardiovasc Res; 2021 Jan; 117(1):320-329. PubMed ID: 32065620
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study.
Kobalava Z; Villevalde S; Kotovskaya Y; Hinrichsen H; Petersen-Sylla M; Zaehringer A; Pang Y; Rajman I; Canadi J; Dahlke M; Lloyd P; Halabi A
Br J Clin Pharmacol; 2015 Jun; 79(6):937-45. PubMed ID: 25511105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
